Table 1 Patient characteristics.

		ABP 980	RTZ	total	P value*
* chi-squared-test; ER = estrogen receptor; PR = progesterone receptor; RTZ = reference trastuzumab
All patients, N		46	78	124
Mean age, years (SD)		51.3 (9.0)	53.7 (10.0)	52.2 (9.4)	0.176
Tumor size, N (%)					0.436
T1		9 (19.6)	16 (20.5)	25 (20.2)
T2		32 (69.6)	47 (60.3)	79 (63.7)
T3–4		5 (10.9)	15 (19.2)	20 (16.1)
Nodal involvement, N (%)					0.063
pN−		25 (54.3)	29 (37.2)	54 (43.5)
pN+		21 (45.7)	49 (62.8)	70 (56.5)
Grading, N (%)					0.024
G2		9 (20.0)	31 (39.7)	40 (32.5)
G3		36 (80.0)	47 (60.3)	83 (67.5)
ER status, N (%)					0.256
negative		17 (37.0)	37 (47.4)	54 (43.5)
positive		29 (63.0)	41 (52.6)	70 (56.5)
PR status, N (%)					0.067
negative		23 (50.0)	52 (66.7)	75 (60.5)
positive		23 (50.0)	26 (33.3)	49 (39.5)
HER2 status, N (%)					0.695
Score 2+		7 (15.2)	14 (17.9)	21 (16.9)
Score 3+		39 (84.8)	64 (82.1)	103 (83.1)
Neoadjuvant chemotherapy, N (%)
Taxane	yes	46 (100.0)	78 (100.0)	122 (100.0)	1.000
Anthracyclines	yes	40 (88.9)	72 (92.3)	112 (91.1)	0.522
	no	5 (11.1)	6 (7.7)	11 (8.9)
Dual HER2-blockade	yes	44 (95.7)	53 (67.9)	97 (78.2)	< 0.001
	no	2 (4.3)	25 (32.1)	27 (21.8)